With the prominence of the Pharmaceutical generics industry growing rapidly each year, it is becoming harder for Big Pharma to dismiss the threat that now exists to their business.
With over half of the current blockbuster drugs on the market with a value of £241 Billion due to expire within five years, there are incredible opportunities open to the existing and upcoming generic players. With even the largest of primary drug manufacturers starting to involve themselves in a serious way.
However despite the opportunities there are still numerous pitfalls. The generic marketplace is rife with litigation & patent infringement cases, Intellectual Property (IP) disputes, production authorisation challenges, and cut-throat competition.
SMi's conference aims to provide an insight into the complexity of the current commercial and legal landscapes surrounding the Generics marketplace, and to keep you up-to-date with future trends and developments.